We are a clinical-stage biopharmaceutical company in Puerto Rico focused on the development and comm
Location: United States, California, Monrovia
Employees: 1-10
Founded date: 2019
Investors 1
| Date | Name | Website |
| - | Myeloma In... | myelomainv... |
Mentions in press and media 4
| Date | Title | Description |
| 07.05.2025 | CytoImmune Therapeutics Positioned to Accelerate U.S. Pharma Reshoring Efforts Amid Executive Order to Boost Domestic Drug Manufacturing | CytoImmune Therapeutics CytoImmune's initial 200% expansion of its commercial monoclonal antibody (mAb) manufacturing capacity will be ready for product transfer and regulatory inspections by 2027, with a second phase planned for 2028. Once... |
| 03.08.2023 | CytoImmune Therapeutics Secures ALPPL2 Portfolio License: A New Milestone in Advancing Cell Therapy Solutions | CytoImmune Therapeutics This acquisition will empower us to present our clients with an even more diversified array of cell therapy solutions, contributing substantially to the growth of off-the-shelf allogeneic cell therapy space and impro... |
| 27.07.2023 | CytoImmune Therapeutics Broadens Services: A New Chapter in Development and Manufacturing of Cell Therapies | CytoImmune Therapeutics Our team is dedicated to advancing the field of cell therapy and helping our partners bring life-changing treatments to patients in need. Toa Baja, Puerto Rico (PRWEB) July 27, 2023 CytoImmune Therapeutics is proud t... |
| 19.07.2023 | CytoImmune Therapeutics Ushers in New Era with Appointment of Dr. Jose Eduardo Vidal as CEO to Spearhead Focus on Cell Therapy Development | Jose Eduardo Vidal, Ph.D. We are committed to developing innovative cell therapies that hold transformative potential for cancer patients. TOA BAJA, Puerto Rico (PRWEB) July 19, 2023 CytoImmune Therapeutics is proud to announce the promotio... |